# A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

> **NCT01886053** · PHASE2 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 189 (actual)

## Conditions studied

- Community Acquired Pneumonia

## Interventions

- **DRUG:** Faropenem（high dose group）
- **DRUG:** Faropenem（low-dose group)
- **DRUG:** Ertapenem

## Key facts

- **NCT ID:** NCT01886053
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2013-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01886053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01886053, "A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01886053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*